Got Patients With Refractory axSpA or PsA? Consider This Option
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
(Medage today)-Although most patients with axial spondyloarthrosis (AXSPA) or psoriatic arthritis (PSA) have not adequately responded to the interleukin-19 inhibitor (IL-17) Ixekizumab (Taltz), sufficiently made that it is always considered in such …
